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Benign transient hyperphosphatasemia (BTH) is a condition which occurs in children younger than 
five years, characterized by a complete absence of specific clinical and laboratory findings of bone 
or liver diseases and a five or even 20–70-fold increase in serum of alkaline phosphatase levels(ALP). 
The aim of this case report was to point out that elevated levels of ALP are not always related to 
serious bone and liver diseases. We described three healthy patients, which were referred to our 
out-patient clinic by their primary care physicians because of markedly elevated levels of ALP. The 
diagnosis of BTH was based on a thorough physical exam, a wide range of laboratory and imaging 
tests, which excluded liver or bone disease as a cause for elevated ALP. BTH is not very well-known 
and managed in daily clinical practice. Primary care physicians should consider this diagnosis in 
cases with elevated ALP in otherwise healthy infants and toddlers, refrain from unnecessary tests, 
prescribing higher doses of vitamin D3 or referral to tertiary level pediatric institutions. 
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Бенигната транзиторна хиперфосфатазија (БТХ) е состојба која се јавува кај деца помлади од 
пет години. Се карактеризира со целосно отсуство на специфични клинички и лабораториски 
наоди за болести на коските и црниот дроб и пет или дури 20-70 пати поголемо зголемување 
на серумското ниво на алкална фосфатаза (АЛП). Целта на овој приказ на случаи беше да 
се истакне дека случаен наод на покачено серумско ниво на АЛП не е секогаш поврзано со 
сериозни заболувања на коските и црниот дроб. Опишавме три здрави пациенти, кои беа упа-
тени во нашата амбуланта од страна на лекари од примарната здравствена заштита поради 
значително зголемено ниво на АЛП. Дијагнозата на БТХ беше заснована на темелен клинички 
преглед, широк спектар на лабораториски тестови, со што беа исклучени заболувања на цр-
ниот дроб и коските како причина за покачена АЛП. БТХ е состојба која не е добро позната и 
менаџирана во секојдневната клиничка пракса. Лекарите од примарната здравствена зашти-
та треба да ја имаат предвид оваа дијагноза во случаи со покачена АЛП кај здрави доенчиња 
и мали деца и да се воздржат од правење непотребни тестови и препишување повисоки дози 
на витамин Д3. 
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Introduction
Alkaline phosphatase (ALP) is one 
of the most commonly ordered 
laboratory tests used to evalu-
ate the presence of rickets, bone 
or liver disorders in pediatric pa-
tients. ALP is an enzyme present in 
placenta,intestinal mucosa, kidney, 
bone and liver, but the majority of 
the alkaline phosphatase in serum 
(more than 80%) is released from liv-
er and bone, and in small amounts 
from the intestine1. It is represent-
ed by four isoenzymes produced by 
bone, liver, intestine and kidney, 
which take part in important meta-
bolic processes like: IgG transporta-
tion during pregnancy, bone forma-
tion, renal and intestinal phosphate 
transportation, fat transportation 
and pancreatic chlorine channels 
regulation 1-3. The serum ALP lev-
els vary by age, with significantly 
higher levels in toddlers and young 
children compared to levels in 
adulthood 4. Although serum ALP 
levels are a sensitive marker for 
bone and liver diseases in children 
and adults, there is a condition 
that is usually found incidentally in 
young children, which is character-
ized by a complete absence of spe-
cific clinical and laboratory findings 
of bone and liver diseases and a five-
fold or even 20–70-fold increase in 
serum ALP. This condition is known 
as benign transient hyperphospha-
tasemia (BTH)2-4. Although there is 
growing scientific evidence in the 
current literature suggesting this 
is a completely benign cause of ex-
cessively elevated ALP, it remains a 
condition under-recognized and not 
very well managed. It is important 
to avoid the unnecessary investiga-
tions or over treatment in patients 
with significant increase in ALP lev-
els.  
The objective of this study was to 
describe three healthy patients, 
which were referred to our out-pa-
tient clinic by primary care physi-
cians because of markedly elevated 
levels of ALP. The diagnosis of BTH 
in our patients was based on their 
clinical and biochemical features, 
meaning a thorough physical exam 
and a wide range of laboratory and 
imaging tests in order to rule out 
liver or bone disease as a cause for 
elevated ALP.
Case reports
We describe the case history of 
three patients who were referred 
to our outpatient clinic in the pe-
riod from 2018 to 2020. The mean 
age of the patients was 19.3 (13-25) 
months; two were girls and one was 
boy. All three toddlers were referred 
under suspicion of having rickets 
because of elevated ALP. The first 
patient, a 13-month-old boy,, was 
referred to the outpatient clinic by 
the child’s primary care physician 
because the child was still unable 
to walk without support. The child 
was initially referred to an orthope-
dist who prescribed cholecalciferol 
4000 IU per day. The second patient, 
a 20-month-old girl had an open an-
terior fontanelle, with measures 1 x 
1 cm and was prescribed cholecal-
ciferol 6000 IU per day. The third 
patient, a 25-month-old girl had a 
slight varus deformity of the lower 
limbs, which prompted the primary 
care physician to seek consultation. 
All children were healthy; physical 
examination was performed, which 
showed that their anthropometric 
measures were within the normal 
range for their age and sex (Table 1). 
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They did not have frontal bossing, 
widening of the wrists or other bone 
deformities suggesting rickets or 
other bone disorders. There was no 
history of dark-colored urine, pru-
ritus, and steatorrhea. The medical 
history of all three patients con-
tained information that the children 
had a viral gastroenteritis two weeks 
prior to the measured elevated ALP.    
A wide panel of laboratory test was 
performed, including: alaninе ami-
notransferase (ALT), aspartate ami-
notransferase (AST), gamma-glu-
tamyl transpeptidase (GGT), calcium, 
phosphate, magnesium, blood urea 
nitrogen, creatinine, ALP, 25-hy-
droxy vitamin D3, PTH and a wrists 
x-ray. All of the results were within 
normal range, excluding the levels of 
ALP which were markedly elevated 
(Table1). The ALP was measured us-
ing a biochemical analyzer (Archi-
tect c4000 Abbot) with a colorimet-
ric assay, based on the conversion 
of para-nitrophenyl phosphate.The 
reference value for children up to 5 
years old is from 81.9 to 350.3 U/L.The 
maximum values of ALP recorded in 
the three patients were: 3400, 2800 
and 2050 UI/L, respectively. The chil-
dren were prescribed a prophylactic 
dose of cholecalciferol. On the first 
follow-up visit after two months, the 
level of ALP was reduced significant-
ly in all three toddlers, compared 
to their first visit (850, 670 and 600 
IU/L, respectively). The next follow-
up at four months, the ALP levels of 
all the three patients had completely 
normalized (180, 120 and 115 IU/L, re-
spectively). By the end of the follow-
up period the first patient was able 
to walk without support and the an-
terior fontanel of the second patient 
had closed completely.
Patient 1 Patient 2 Patient 3
age 13 months 20 months 23 months
sex male female female
Height Z score
Weight Z score
+1.5
+0.8
+1
+1.2
+1.8
+1.6
AST (N.15-59 U/L) 13 25 18
ALT   (N.9-72U/L 10 15 27
GGT (N.0-36U/L) 9 30 28
LDH(N.0-500U/L) 344 284 249
Ca (N.2.10-2.55 mmol/L) 2.20 2.15 2.43
P (N.0.85-2.15mmol/L) 1.5 2.02 1.8
Mg (N.0.70-1.0mmol/L 0.8 0.98 1.1
BUN (N.2.6-6.4mmol/L) 3.5 4.9 6.0
Creatinine(N.0-104mmol/L) 60 54.4 75
ALP(N.0-120U/L) 2050 2800 3400
25(OH)Vit D3(N.20-50ng/ml) 33 45 20
PTH(N.10-65pg/ml) 40 24 60
alaninе aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), calci-
um (Ca), phosphate (P), magnesium (Mg), blood urea nitrogen (BUN), 25-hydroxy vitamin D3, parathormone (PTH)
Table 1.  Anthropometric characteristics and results from laboratory tests in our patients 
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Discussion
BTH is a cause for markedly elevat-
ed ALP levels in childhood, but it is 
a transient, completely benign con-
dition which requires no specific 
treatment (5). In a study by Suzuki et 
al. from 2002, it was suggested that 
the most probable cause for BTH 
was a recent еnteroviral infection6, 
while other studies have suggested 
that this condition is a biochemical 
problem rather than an illness7,8,9. 
The first description of this condi-
tion was made by Bach in 19545, but 
the diagnostic criteria were defined 
years later, in 1985 by Kraut et al 10 
and they include: age of presenta-
tion less than five years; no other 
evidence for bone or liver disease 
on physical examination or labo-
ratory findings; elevation in both 
bone and liver ALP isoenzymes; and 
normalization of serum ALP levels 
within four months. A presumptive 
diagnosis of BTH was made by Chu 
et al.11, which incorporated Kraut‘s 
original diagnostic criteria, but up-
dated with more recent relevant 
literature, including ALP levels sig-
nificantly elevated  (median values 
nine-fold the upper limit of normal), 
which return to normal within 3 to 
4 months; age less than five years; 
history and physical examination 
non-confirmatory for  bone or liver 
disease; normal liver tests; normal 
electrolytes, blood urea nitrogen and 
creatinine; an absolute elevation of 
both bone and liver fractions of ALP 
isoenzymes; normal levels of PTH 
and 25-hydroxy vitamin D. The clini-
cal course and the ALP levels of the 
patients described in this study were 
similar to those reported in the pub-
lished literature4-6.The evaluation of 
the patient with a detailed history, a 
thorough physical examination and 
baseline laboratory tests is generally 
sufficient to exclude possible liver 
or bone disease. The primary diag-
nostic concerns when encountering 
elevated ALP levels in children in-
clude: bone disorders, liver disease, 
less commonly kidney disease and 
drug reactions (anticonvulsants, an-
tibiotics)7,8. Specific inquiries should 
be made about the presence of 
symptoms indicating hepatobiliary 
disease and signs of rickets8. Com-
pared to other causes for elevated 
ALP, the peak value of ALP in BTH 
can be from 3 to 30-fold above upper 
reference range7. According to a re-
cent study, the ALP was elevated at 
least 5 times from the upper normal 
limit in 71% of patients with BTH12. It 
has been suggested that intermediate 
elevations of less than 5 times than 
normal may possibly represent either 
developing or resolving BTH13. In our 
patients, ALP levels were at least nine 
times higher than normal upper limit 
(between 2050 and 3400 IU/L).                                 
In conclusion, even though almost 
half a century has passed since the 
first reported case of BTH in early 
childhood, it is rarely mentioned in 
the literature and takes up a small 
place in textbooks; it is not very well-
known and managed in daily clini-
cal practice. We have reported three 
cases of toddlers with BTH who are 
a good example of a basic medicine 
lesson:“Don’t treat the lab results, 
treat an illness“. Primary care physi-
cians should consider this diagnosis 
in cases with elevated ALP in healthy 
infants and toddlers, avoid unneces-
sary investigations, prescribing high-
er doses of vitamin D3 or referral to 
tertiary level pediatric institutions. 
References
1. Ridefelt P, Gustafsson J, Aldrimer 
M, Hellberg D. Alkaline phospha-
tase in healthy children: reference 
intervals and prevalence of elevat-
ed levels. Horm Res Paediatr 2014; 
82(6): 399-404.
9
АРХИВИ НА ЈАВНОТО ЗДРАВЈЕ
2. Pace AE, Osinde ME. Hiperfosfa-
tasemia transitória benigna de la 
infância. Uma aproximación diag-
nóstica racional. Arch Argent Pedi-
atr 1999;97:383-90.        
3. Melo MCN, Carneiro NB, Tolaymat 
N, et al. Hiperfosfatasemia tran-
sitória benigna na infância. Rev 
Cienc Med Biol 2004;3:108-14.
4. Tolaymat N, de Melo MC. Benign 
transient hyperphosphatasemia of 
infancy and childhood. South Med J 
2000;93:1162–4. 
5. Bach U; Das verhalten der alka-
lischen serumphosphatase bei 
Frughgerborenen. Rachitikern und 
Spasmophilen. Z Kinderheilk 1954; 
74: 593-609. 
6.  Suzuki M, Okazaki T, Nagai T, Törõ 
K, Sétonyi P. Viral infection of in-
fants and children with benign tran-
sient hyperphosphatasemia. FEMS 
Immunol Med Microbiol 2002; 33(3): 
215–8.
7. Carroll AJ, Coakley JC. Transient hy-
perphosphatasaemia: an important 
condition to recognize. J Paediatr 
Child Health 2001;37:359–6.
8. Kutilek S, Cervickova B, Bebova P, 
Kmonickova M, Nemec V. Normal 
bone turnover in transient hyper-
phosphatasemia. J Clin Res Pediatr 
Endocrinol 2012; 4(3): 154-156.
9. Otero JL, Gonzalez-Peralta RP, An-
dres JM, Jolley CD, Novak DA, Haafiz 
A. Elevated Alkaline Phosphatase in 
children: an algorithm to determine 
when a “wait and see” approach is 
optimal. Clin Med Insights Pediatr 
2011; 5:15-8.
10. Kraut JR, Metrick M, Maxwell NR, 
Kaplan MM. Isoenzyme studies in 
transient hyperphosphatasemia of 
infancy: ten new cases and a review 
of the literature. Am J Dis Child 
1985; 139(7): 736-40. 
11. Chu AS, Rothschild JG. Update on 
benign transient hyperphosphatas-
emia: recognizing an underappreci-
ated condition. Clin Pediatr (Phila) 
2016; 55(6): 564-6.
12. Gualco G, Lava SA, Garzoni Let al. 
Transient benign hyperphosphatas-
emia. J Pediatr Gastroenterol Nutr 
2013; 57(2): 167-71.
13. Asanti R, Hultin H, Visakorpi JK. 
Serum alkaline phosphatase in 
healthy infants: occurence of ab-
normality high values without 
known cause. Ann Paediatr Fenn 
1966; 12(2): 139-42.
